BOUYGUES SA (EN.PA)       30.58  +0.16 (+0.53%)

30.58  +0.16 (+0.53%)

FR0000120503 - Common Stock


Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EN. EN was compared to 20 industry peers in the Construction & Engineering industry. EN has a bad profitability rating. Also its financial health evaluation is rather negative. A decent growth rate in combination with a cheap valuation! Better keep an eye on EN.




Profitability

Profitability Rating

1

The Piotroski-F score of EN is 4.00. This is a neutral score and indicates average health and profitability for EN.
EN has a Return On Assets of 1.61%. This is below the industry average of 4.70%. 80% of the industry peers outperform EN.

EN has a Return On Equity of 7.97%. This is below the industry average of 18.79%.
EN's Profit Margin of 2.20% is worse than the rest of the industry. The industry average Profit Margin is 3.29%.
VS Industry

ROA (1.61%) VS Industry: 20% outperformed.

0.39
41.00

ROE (7.97%) VS Industry: 26% outperformed.

0.84
193.11

Profit Margin (2.2%) VS Industry: 23% outperformed.

0.34
24.74

Valuation

Valuation Rating

7

With a Price/Earnings Ratio of 11.99, the valuation of EN can be described as very reasonable.
With a Forward Price/Earnings Ratio of 9.51, the valuation of EN can be described as very reasonable.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a price book ratio of 0.92, EN is valued rather cheaply.

Compared to an average industry Enterprise Value to EBITDA ratio of 5.53, EN is valued rather cheaply
Compared to an average industry Price/Earning Ratio of 11.99, EN is valued in line with its industry peers.
When comparing the price book ratio of EN to the average industry price book ratio of 1.10, EN is valued in line with its industry peers.
VS Industry

Price/Earnings (11.99) VS Industry: 47% outperformed.

41.56
0.56

Price/Book (0.92) VS Industry: 58% outperformed.

6.26
0.09

Enterprise Value/ EBITDA (4.54) VS Industry: 76% outperformed.

21.28
1.25

Growth

Growth Rating

5

The Earnings Per Share is expected to grow by 13.68% on average over the next 5 years. This is quite good.
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
Looking at the last year, EN shows a quite strong growth in Revenue. The Revenue has grown by 17.91% in the last year.
EN shows a decrease in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -3.26% yearly.

Measured over the past 5 years, EN shows a small growth in Revenue. The Revenue has been growing by 6.13% on average per year.
EN is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 4.63% yearly.
The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
EN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.56%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-3.26% -7% -13.56% 26.09% 20.87% 18.96% 13.68%
Revenue6.13% 5.33% 17.91% 22.32% 10.3% 6.26% 4.63%

Health

Health Rating

2

The Quick Ratio of EN is much better than the industry average of 0.84.
The Current Ratio is in line with the industry averages, which is at 1.10.
The Piotroski-F score of EN is 4.00. This is a neutral score and indicates average health and profitability for EN.
EN has a Current Ratio of 0.98. This is a bad value and indicates that EN is not financially healthy enough and could expect problems in meeting its short term obligations.

EN has a Quick Ratio of 0.98. This is a bad value and indicates that EN is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Debt to Equity Ratio of EN to the average industry Debt to Equity Ratio of 0.54, EN required more debt to finance its operations than its industry peers.
EN has an Altman-Z score of 0.99. This is a bad value and indicates that EN is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.71, EN is in worse financial health than its industry peers.
VS Industry

Debt/Equity (1.12) VS Industry: 29% outperformed.

5.04
0.09

Quick Ratio (0.88) VS Industry: 64% outperformed.

0.22
1.40

Current Ratio (0.98) VS Industry: 41% outperformed.

0.23
1.46

Altman-Z (0.99) VS Industry: 25% outperformed.

0.60
3.94

Dividend

Dividend Rating

7

EN has a Yearly Dividend Yield of 5.59%, which is a nice return.
EN's Dividend Yield is rather good when compared to the S&P500 average which is at 2.60.
EN's earnings are growing more than its dividend. This makes the dividend growth sustainable.

Compared to an average industry Dividend Yield of 5.59, EN has a dividend in line with its industry peers.
The dividend of EN has a limited annual growth rate of 1.92%.
69.89% of the earnings are spent on dividend by EN. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (5.59%) VS Industry: 50% outperformed.

1.22
29.30

BOUYGUES SA30.58

EPA:EN (3/29/2023, 9:52:16 AM)+0.16 (+0.53%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.21B
Analysts76.52
Price Target34.73 (13.57%)
Dividend
Industry RankSector Rank
Dividend Yield 5.59%
Dividend Growth(5Y)1.92%
DP69.89%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.03%
Min EPS beat(2)-8.31%
Max EPS beat(2)58.37%
EPS beat(4)3
Avg EPS beat(4)18.93%
Min EPS beat(4)-8.31%
Max EPS beat(4)58.37%
Revenue beat(2)2
Avg Revenue beat(2)9.4%
Min Revenue beat(2)0.56%
Max Revenue beat(2)18.25%
Revenue beat(4)2
Avg Revenue beat(4)4.37%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)18.25%
PT rev (1m)0.02%
PT rev (3m)-3.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.94%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-0.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)10.29%
Revenue NY rev (3m)10.29%
Valuation
Industry RankSector Rank
PE 11.99
Fwd PE 9.51
P/S 0.25
P/FCF 31.74
P/OCF 3.76
P/B 0.92
P/tB N/A
EV/EBITDA 4.54
EPS(TTM)2.55
EY8.34%
EPS(NY)3.22
Fwd EY10.51%
FCF(TTM)0.96
FCFY3.15%
OCF(TTM)8.13
OCFY26.58%
SpS120.95
BVpS33.33
TBVpS-11.96
PEG (NY)0.46
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.61%
ROE 7.97%
ROIC 4.46%
ROICexc 5.48%
ROICexgc 15.89%
OM 4.33%
PM 2.2%
GM 56.43%
ROICexgc(3y)15.94%
ROICexcg growth 3Y0.9%
ROICexcg growth 5Y-1.55%
ROICexc(3y)6.01%
ROICexc growth 3Y-9.42%
ROICexc growth 5Y-7.06%
OM growth 3Y-1.1%
OM growth 5Y-1.28%
PM growth 3Y-11.07%
PM growth 5Y-7.75%
GM growth 3Y1.94%
GM growth 5Y1%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF 45.24
Debt/EBITDA 3.47
Cap/Depr 97.77%
Profit Quality 36.28%
Current Ratio 0.98
Quick Ratio 0.88
Altman-Z 0.99
F-Score4
WACC5.15%
ROIC/WACC3.08
Cap/Depr(3y)105.65%
Cap/Depr(5y)102.01%
Profit Quality(3y)81.88%
Profit Quality(5y)80.99%
Growth
EPS 1Y-13.56%
EPS 3Y-7%
EPS 5Y-3.26%
EPS growth Q2Q36.9%
EPS Next Y26.09%
EPS Next 2Y20.87%
EPS Next 3Y18.96%
EPS Next 5Y13.68%
Revenue growth 1Y17.91%
Revenue growth 3Y5.33%
Revenue growth 5Y6.13%
Revenue growth Q2Q45.4%
Revenue Next Year22.32%
Revenue Next 2Y10.3%
Revenue Next 3Y6.26%
Revenue Next 5Y4.63%
EBIT growth 1Y12.24%
EBIT growth 3Y4.17%
EBIT growth 5Y4.76%
EBIT Next Year152.69%
EBIT Next 3Y40.86%
EBIT Next 5Y28.78%
FCF growth 1Y-68.76%
FCF growth 3Y-38.53%
FCF growth 5Y22.49%
OCF growth 1Y-16.72%
OCF growth 3Y-4.07%
OCF growth 5Y7.66%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext